These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Mood stabilizers in the treatment of juvenile bipolar disorder. Advances and controversies. Davanzo PA; McCracken JT Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):159-82. PubMed ID: 10674195 [TBL] [Abstract][Full Text] [Related]
46. Divalproex in the treatment of bipolar depression: a placebo-controlled study. Davis LL; Bartolucci A; Petty F J Affect Disord; 2005 Apr; 85(3):259-66. PubMed ID: 15780695 [TBL] [Abstract][Full Text] [Related]
47. Delirium and persistent dyskinesia induced by a lithium-neuroleptic interaction. Normann C; Brandt C; Berger M; Walden J Pharmacopsychiatry; 1998 Sep; 31(5):201-4. PubMed ID: 9832353 [TBL] [Abstract][Full Text] [Related]
48. Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. Kilbourne AM; Post EP; Bauer MS; Zeber JE; Copeland LA; Good CB; Pincus HA J Affect Disord; 2007 Sep; 102(1-3):145-51. PubMed ID: 17276514 [TBL] [Abstract][Full Text] [Related]
49. [Clinical standing of valproate treatment of bipolar disorders]. Grunze H; Adli M; Bauer M; Berger M; Bergmann A; Bräunig P; Bschor T; Falkai P; Gastpar M; Greil W; Kasper S; Krüger S; Laux G; Müller WE; Naber D; Walden J Fortschr Neurol Psychiatr; 2007 Apr; 75(4):220-35. PubMed ID: 17427043 [TBL] [Abstract][Full Text] [Related]
50. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Scott J; Pope M Am J Psychiatry; 2002 Nov; 159(11):1927-9. PubMed ID: 12411230 [TBL] [Abstract][Full Text] [Related]
51. Hormonal effects of valproic acid? Garland EJ; Behr R J Am Acad Child Adolesc Psychiatry; 1996 Nov; 35(11):1424-5. PubMed ID: 8936907 [No Abstract] [Full Text] [Related]
52. Pharmacokinetics of valproic acid in patients with bipolar disorder. Vasudev K; Das S; Goswami U; Tayal G J Psychopharmacol; 2001 Sep; 15(3):187-90. PubMed ID: 11565626 [TBL] [Abstract][Full Text] [Related]
54. Correlation of valproate plasma concentrations and dose in bipolar affective disorder. Perry PJ; Bever-Stille KA; Arndt S; Gundersen S J Clin Psychopharmacol; 2000 Apr; 20(2):277-9. PubMed ID: 10770477 [No Abstract] [Full Text] [Related]
55. Case of significantly delayed divalproex-induced thrombocytopaenia. Park A; Shapiro B; Hedayati B; Faziola L BMJ Case Rep; 2019 Dec; 12(12):. PubMed ID: 31796434 [TBL] [Abstract][Full Text] [Related]
56. Mood stabilizers in Asperger's syndrome. Duggal HS Aust N Z J Psychiatry; 2001 Jun; 35(3):390-1. PubMed ID: 11437822 [No Abstract] [Full Text] [Related]
57. [Valproic acid in prophylaxis of bipolar disorder. A case of valproate-induced encephalopathy]. Rottach KG; Weiss-Brummer J; Wieland U; Schmauss M Nervenarzt; 2000 May; 71(5):401-3. PubMed ID: 10846716 [TBL] [Abstract][Full Text] [Related]
58. Risperidone, a risk factor for valproate-induced encephalopathy? Rodrigues-Silva N; Venâncio Â; Bouça J Gen Hosp Psychiatry; 2013; 35(4):452.e5-6. PubMed ID: 23317937 [TBL] [Abstract][Full Text] [Related]
59. Intravenous valproate treatment of severe manic symptoms after gastric bypass surgery: a case report. Kaltsounis J; De Leon OA Psychosomatics; 2000; 41(5):454-6. PubMed ID: 11015641 [No Abstract] [Full Text] [Related]
60. Fulminant hepatic failure in the context of reinstituting valproate use. Rej S; Chen T; Edwards M; Zicherman V Psychosomatics; 2014; 55(3):303-4. PubMed ID: 24360531 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]